What if the word "vulvodynia" has been obscuring the real picture all along - and your pain has a more specific cause that can actually be targeted?
Dr. Jill Krapf is a vulvovaginal pain specialist at The Centers for Vulvovaginal Disorders and the co-author of "When Sex Hurts." She is one of the most followed clinicians in this space (@jillkrapfmd) and is known for her clear, evidence-based communication about conditions that mainstream medicine consistently under-explains. In this episode, Dr. Krapf argues that the catch-all term "vulvodynia" may eventually disappear as research identifies specific root causes - and walks through what those causes actually are, how she investigates them in practice, and what targeted treatment looks like.
Why "vulvodynia" is a problematic term - and what we know instead
Vulvodynia is a descriptive diagnosis - it means chronic vulvar pain without an identifiable cause. Dr. Krapf's view is that this is a category that reflects the limits of our current understanding rather than a real clinical entity: that for most patients, there is an identifiable cause, it's just that the investigative tools and clinical knowledge to find it have been slow to reach standard medical practice. She expects the term to eventually be retired as specific subtypes are defined and validated.
The practical implication for patients is significant. If vulvodynia is not one condition but a collection of overlapping conditions with different root causes, then treatment based on a generic diagnosis - or on the assumption that the cause is unknown - is likely to underperform. The shift toward root-cause investigation changes what is possible in treatment, and Dr. Krapf's practice is built around that approach.
"There's generally four buckets of cause if we really want to break it down in a very simplified fashion. The first bucket is hormone related and that can encompass discrete diagnoses we already have, like genitourinary syndrome of menopause, as well as all of these other potential causes due to medications like birth control pills."
The four root-cause categories: hormonal, muscular, inflammatory, and nerve-related
Dr. Krapf organises her root-cause framework into four main categories. Hormonal factors - including the effects of hormonal contraception on vaginal tissue, low oestrogen states, and hormonal fluctuation across the menstrual cycle - are among the most common and most treatable. Muscular causes involve the pelvic floor: hypertonicity, spasm, and the pain cycles that develop when muscle tension and pain reinforce each other. Inflammatory and infectious factors include conditions like vestibulitis, mast cell activation, and the aftermath of recurrent thrush. Nerve-related pain involves peripheral sensitisation and, in more complex cases, pudendal or pelvic nerve involvement.
These categories frequently overlap - a hormonal factor may drive inflammation which drives pelvic floor tension which creates a nerve-sensitisation pattern - and effective treatment often needs to address multiple drivers simultaneously. Dr. Krapf discusses how she assesses which factors are present in individual patients and how she prioritises them in treatment planning.
"There's literature showing that there's mast cell presence and proliferation in some of these cases, especially when there's amplification of the nerve endings in these areas as well - which kind of brings us to the fourth bucket of cause."
Hormonal treatment, pelvic floor therapy, and when to consider surgery
Topical oestrogen and testosterone are among the most underused treatments in vulvodynia, despite strong evidence for their effectiveness in hormonally-driven presentations. Dr. Krapf discusses who is likely to respond, how to assess for a hormonal component, and what to expect from treatment. She is also clear about where topical hormones are not the answer - and what the other treatment pathways look like.
On the question of surgery, she provides important context: vestibulectomy is not a first-line treatment, but for the right patient - typically those with localised provoked vestibulodynia with a clear inflammatory driver who have not responded to conservative treatment - the evidence supports it. The conversation around vestibulectomy is often distorted by fear and misinformation, and Dr. Krapf's clinical experience with it is a useful corrective.
"In order to have a treatment for something, you really need to identify what the cause is. And that is really an interesting issue - and that's why root-cause investigation matters so much."
New research on neuroinflammatory pain and what it means for treatment
One of the most exciting areas of current vulvodynia research involves neuroinflammatory mechanisms - the role of immune cells, particularly mast cells, in maintaining a state of peripheral nerve sensitisation in the vestibular tissue. Dr. Krapf discusses what is currently known, what clinical trials are investigating, and why this line of research matters for patients whose pain hasn't responded to the standard treatment categories.
For people who have worked through hormonal treatment, pelvic floor physiotherapy, and pain management without achieving adequate relief, understanding the neuroinflammatory pathway and the emerging treatments targeting it - including mast cell stabilisers - may be the most valuable section of this episode. It represents the frontier of what is clinically possible, and knowing it exists changes what questions to bring to a specialist appointment.
